

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

AVRAMIS ET AL.

APPLICATION NO: 10/505,399

FILED: AUGUST 19, 2004

FOR: COMBINATIONS OF (A) AN ATP-COMPETITIVE INHIBITOR OF C-ABL KINASE ACTIVITY WITH (B) TWO OR MORE OTHER ANTINEOPLASTIC AGENTS

**MS: Petition**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

PETITION TO REVIVE UNDER 37 C.F.R. 1.137(b)

Sir:

Applicants believe that this application has gone abandoned for failure to timely respond to the Office action dated February 1, 2008 and hereby petition to revive said application under 37 C.F.R. 1.137 because the abandonment was unintentional.

In accordance with 37 C.F.R. 1.137(b):

(1) Applicants submit herewith a reply to the outstanding Office action and a Petition for Extension of time.

(2) Applicants hereby authorize the Commissioner to charge Deposit Account No. 19-0134 in the name of Novartis the amount of \$1540 as required by 37 C.F.R. 1.17(m) and any other required fees.

(3) The undersigned hereby states that the entire delay from the due date for the reply to the filing of this petition was unintentional.

(4) No terminal disclaimer is required in accordance with 37 C.F.R. 1.137(d).

Novartis Pharmaceuticals Corp.  
Patents Pharma  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7824

Date: *DP-2P-DP*

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "George R. Dohmann", written over a horizontal line.

George R. Dohmann  
Attorney for Applicants  
Reg. No. 33,593